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Case Report
Abstract
Intra-cranial melanomas are commonly metastatic from primary melanoma elsewhere in the body. The primary occurrence of a
melanoma in the brain parenchyma is rare. We report a case of 38 year aged woman who presented with deviation of left eye
and headache. On imaging, a space occupying lesion was found in the left Cerebello-pontine angle and a preoperative diagnosis
of meningioma was made. She underwent left retro-mastoid sub-occipital craniectomy and excision of a black vascular tumor.
Histopathological examination revealed a melanoma which was confirmed with Immunohistochemical assay. Search for dermal,
mucous and ocular lesions were negative. She received adjuvant radiation to the post- operative tumor bed to 5400cGy in 30
fractions using Intensity Modulated Radiation Therapy technique along with concurrent Temozolomide. She tolerated the
treatment well and is symptom free 12 months after treatment. Primary Melanomas are rare lesions of the Cerebello-pontine
angle and its radiological features, evaluation and management have been discussed.
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Introduction
Primary melanocytic lesions are rare tumors of Central
Nervous System (CNS) with an incidence of 0.9 per 10 mil-
lion.1, 2 Though these tumors are seen anywhere along the
leptomeningeal axis, they specifically cluster around the
Brain stem and high cervical spinal cord because of high
aggregation of melanocytes in the leptomeninges at these
locations.3-5 The melanotic cells originate either from em-
bryonic neuroectodermal cell rests or from the pial sheaths
of the vasculature in the CNS.6 Focal tumors range from be-
nign melanocytomas to malignant melanomas. Primary focal
malignant melanomas are even rarer and account for 1% of
all melanoma cases in the CNS.6 The diagnosis is essentially
by exclusion of melanomas in the skin, mucosal membranes
and eyes.4 Total excision, if achieved, results in longer sur-
vival. Adjuvant Radiation has a role in cases of incomplete or
near-total excision.4 Temozolomide is an oral alkylating
agent which crosses the Blood Brain Barrier (BBB) and is
known to be effective in brain metastasis from malignant
melanomas.7, 8 We reported a case of rare primary CNS ma-
lignant melanoma at Cerebello-pontine (CP) angle, managed
successfully with gross total resection (GTR) and adjuvant
radiotherapy along with concomitant Temozolomide. To the
best of our knowledge this is the first case of primary CNS
melanoma managed with concurrent Temozolomide.
Case Report
A thirty-eight-year woman presented to us with a history of
medial deviation of the left eye (Figure 1) and double vision
of two and a half years duration. She also complained of in-
termittent head ache of one year duration. Left eye showed
hypertropia along with esotropia with IV and VI nerve palsy.
Left pupil was mid-dilated, 5 mm in diameter and was reac-
tive. Right pupil was normal. Corneal sensations were nor-
mal. Left Superior Oblique showed no intorsion on depres-
sion in adducted position.
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FIG. 1: Clinical photograph showing medial deviation of the left eye.
FIG. 2: Shows MRI brain with A) Sagittal T1W view with arrow showing a peripheral hyperintense rim on the isointense CP angle tumor;
B) Axial T2W images; C) Susceptibility weighted images with peripheral rim; D) and E) contrast coronal and axial images with homogenous
enhancement.
Plain and contrast magnetic resonance imaging (MRI) of the
brain revealed an extra-axial, dural based lesion in the poste-
rior part of the left CP angle adjacent to the petrous with a
broad base. The lesion was compressing left Cerebellar Hem-
isphere. It was uniformly isointense on T1W images with a
peripheral rim of hyper intensity, isointense on T2W images
with a focal area of hyper intensity in the adjacent Cerebel-
lum and showed homogeneous contrast enhancement. Pe-
ripheral rim of the lesion was well defined on susceptibility
weighted image (SWI). VII-VIII nerve complex and the in-
ternal auditory canal were free from invasion. The rest of the
brain was normal. With these features, a preoperative diag-
nosis of left CP angle Meningioma was made. (Figure 2A - E).
She underwent left retro mastoid sub-occipital craniectomy
and gross total resection of the tumor. The tumor was jet
black in colour (Figure 3), attached to the overlying menin-
ges, soft and friable. Pial breach of the adjacent cerebellar
folia was noted. Dural attachment of the tumor was coagu-
lated after resection. Post-operative recovery was uneventful.
FIG. 3: Jet black tumor attached to the Dura.
FIG. 4: A) Tumor with areas of Hemorrhages (arrow);B) Tumor cells
with enlarged nuclei and single prominent nucleoli;C) Tumor with
increased mitosis and HMB-45 positivity (inset).
Histopathological examination revealed a cellular tumor
composed of relatively monotonous tumor cells in lobules
separated by broad trabeculae. Areas of hemorrhage (Figure
4A) were noted in between. Tumor cells had enlarged round
nuclei with single prominent nucleolus (Figure 4B). It was
richly vascular and contained perivascular siderophages and
melanophages. Focal areas within tumor showed fine melanin
pigment in the cytoplasm. Extensive brain parenchymal in-
filtration by numerous tumor cell lobules was noted.
Immunohistochemistry was strongly positive for HMB-45
(Figure 4C) in all tumor cells suggesting melanocytic origin.
S-100 and Vimentin were also positive. Possibility of a men-
ingioma was ruled out as tumor was negative for an Epithelial
Membrane Antigen (EMA). The MIB index of 8% at certain
foci and 3 - 4% in other areas made us to consider this par-
ticular tumor a malignant one. The histopathological diagno-
sis was that of a CP angle malignant melanoma.
Post-operative contrast MRI showed complete tumor exci-
sion and normal posterior fossa (Figure 5).
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FIG. 5: Post op MRI showing complete excision.
FIG. 6: A, B Radiotherapy planning CT images in axial and sagittal
views delineating the target volume (pink line) and isodose distribu-
tion (blue line) conforming to the target volume avoiding dose to the
adjacent brain stem and spinal cord.
FIG. 7: Dose Volume Histogram showing Radiation dose to the surrounding vital structures within acceptable limits.
A detailed search for a primary melanoma was undertaken.
Dermoscopy revealed no cutaneous lesions. Fundoscopy and
B-scan in the eyes did not reveal any ocular lesions. ENT
examination was normal. Postoperative Flourodeoxy Glu-
cose-Positron Emission Computed Tomography (18F
FDG-PET CT) did not show any abnormal uptake elsewhere
in the body or in the primary site. The final diagnosis was a
primary (nodular) malignant melanoma of Left CP angle with
cerebellar infiltration.
She received adjuvant radiation in conventional fractionation
to a total dose of 5400 cGy in 30 fractions, 180cGy per frac-
tion, five days per week to the tumor bed on 6MV Linear
Accelerator using Intensity Modulated Radiation Therapy
(IMRT- Figure 6A, B) technique. She also received concur-
rent oral Temozolomide. The Dose Volume Histogram (DVH)
showed adequate isodose coverage to the Planning Target
Volume (PTV) while sparing the adjacent normal tissues
(Figure 7). The daily dose of Temozolomide was 75mg/metre
square body surface area (BSA) to a dose of 100mg during
Radiation for a period of six weeks. She tolerated the treat-
ment well. Now at one year after diagnosis and surgery, she is
asymptomatic, on a regular follow-up and is back to work
with persistent (L) VI nerve palsy. One year follow-up MRI of
the brain showed no recurrent mass (Figure 8).
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FIG. 8: One year follow-up MRI showing no tumor recurrence.
Discussion
Primary CNS melanocytic lesions can be broadly classified as
diffuse leptomeningeal melanomatosis or focal melanocytic
tumors. Diffuse lesions may arise de novo or can be a part of
congenital neurocutaneous phakomatosis. Diffuse variety
with leptomeningeal spread present with meningism, raised
intracranial pressure and cranial nerve palsies.2, 3The clinical
presentation of focal tumors depends on the location of the
tumor.
Melanotic Schwannoma and Meningioma acquire melanin
and they need to be considered in differential diagnosis of
CP angle lesions with T2 shortening. Other pigmented le-
sions include Medulloblastoma, Choroid plexus papilloma
and Astrocytoma.2Phang et al., reviewed 24 cases of CP an-
gle melanocytomas and noted that the mean age at presenta-
tion was 44.4 years, men were more frequently affected and
symptoms persisted for an average of 5 months before diag-
nosis. MRI was typically T1 hyper and T2 hypo intense
(melanotic).9 Melanomas are commonly hyper dense lesions
(hemorrhage), with uniform or peripheral enhancement on
CT scans.1 MRI of malignant melanoma of the CNS have two
patterns viz, Melanotic and Amelanotic. Melanotic melano-
mas are typically hyper intense on T1W images and undergo
T2 shortening to become hypo intense due to the paramag-
netic effect of Melanin and blood products. Bleeding within
the tumor can result in hetero-intense signals on MRI.
Amelanotic melanomas are either iso or hypo on T1W imag-
es and iso to hyper intense on T2W scans.10 However Arriaga
et al. noted that Amelanotic pattern on MRI was common at
CP angle.10 Our patient had an amelanotic pattern, with
atypical thin peripheral hyper intense rim on T1W scans
which was well defined on SWI suggesting hemorrhage.3,10
Hayward in 1976 had defined primary CNS malignant mel-
anomas based on clinical findings. According to him, solitary
cerebral lesion, intramedullary or leptomeningeal involve-
ment, hydrocephalus and pineal/pituitary tumors could be
primary melanomas if no melanomatous lesion was found
outside CNS.11A meticulous search for a cutaneous, mucosal
or ocular primary melanoma should prove unrevealing be-
fore a malignant melanoma can be accepted as indigenous to
the CNS. In cases of CNS Melanomas, a workup for primary
lesion picks an extra cranial tumor in approximately 90% of
cases and 10% remain occult.3 Along with Cranial MRI, 18F -
FDG PET CT completes the search for primary.12, 13Whole
body FDG PET CT is highly accurate (91%) in diagnosing
loco regional involvement and staging of melanoma.12
Based on MIB-1 staining, focal lesions can be further classi-
fied as benign melanocytomas (0% - 2%), intermediate grade
melanocytic neoplasms (1% - 4%) and malignant melanomas
(2% - 15%).14Benign melanocytomas typically have variably
pigmented melanocytic cells arranged in tight nests, sheets,
or fascicles. In contrast, malignant melanomas have larger,
cytologically atypical, pigmented tumor cells growing in
loose nests or sheets, often with CNS invasion or necrosis.14
HMB-45 is an antimelanosomal antibody, which is specific
for melanocytic tumors. It was found positive in 86% - 97%
of melanocytic tumors. S-100 is a sensitive marker for cells of
Neural crest origin and lacks specificity.13, 14 Both HMB-45
and S-100 were positive in our patient.
Prognosis in primary CNS malignant melanomas depends
upon the location, extent of tumor excision, involvement of
leptomeninges and MIB-1 labelling index.2 Diffuse lep-
tomeningeal melanosis, though benign, carry dismal progno-
sis with a mean survival of 6.7 months.2, 15 Focal melanomas
have a better prognosis with total excision. Overall survival
upto 28 years have been reported after total resection of the
tumor. In a study by Rodriguez et al, the mean survival of
patients who underwent gross total removal, biopsy and
subtotal removal, and no surgery was 19.58 ± 2.3 months,
9.30 ± 2.4 months, and 3.40 ± 0.7 months respectively.16
There are no treatment guidelines as these tumors are rare.
Surgery remains the key modality of treatment. Subarach-
noid spread of melanomas following surgery is known.2, 3
Sometimes total excision becomes difficult in CP angle tu-
mors due to brain infiltration.2 In a review, 80% of the cases
with subtotal resection of CP angle melanocytomas died
within 12 months of diagnosis.10 There are no effective adju-
vant therapy guidelines. We treated our patient with
post-operative radiation therapy as the literature suggests
better recurrence free period.3 Wadasadawala et al. used
adjuvant radiation up to 5400 cGy in conventional fractiona-
tion.4
As the histopathology showed rich infiltration of the cere-
bellar foliae and high MIB-1 labelling index (8%) suggesting
high mitosis, this tumor was considered to be highly malig-
nant and hence we considered adjuvant Radiation. Although
Melanomas are known to be chemo-resistant, there are re-
cent reports on the use of chemotherapeutic agents. Te-
mozolomide and Dacarbazine (DTIC) have been used in ma-
lignant melanoma with brain metastasis.2, 7 Temozolomide
was safe and with the ability to cross BBB, demonstrated
activity in melanomatous brain metastasis.7 In a randomized
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trial comparing Temozolomide and Dacarbazine in patients
with metastatic melanoma brain, the Temozolomide group
showed comparable survival benefits with improved quality
of life.7 A retrospective study done by Paul MJ et al. com-
pared Temozolomide and DTIC in patients with advanced
malignant melanoma. Results showed significant reduction
in CNS relapse in the Temozolomide group compared to
DTIC at 19 months follow-up.8As Temozolomide has already
been used in metastatic malignant melanoma of CNS with
positive results and as the Primary CNS melanomas have
similar cell lineage, Temozolomide was chosen as the
chemotherapeutic agent.7, 8 The patient tolerated the therapy
satisfactorily. The role of concurrent Temozolomide in the
adjuvant setting needs further evaluation both in primary
and metastatic CNS melanomas. She is planned for a close
long term follow up as it is still early in the disease.
Conclusion
Primary CNS melanoma is difficult to diagnose preopera-
tively. Typically the MRI picture, gross features of the tu-
mor, MIB-1 proliferative index, immunohistochemistry and
18 F-FDG PET CT plays a major role in the diagnosis of pri-
mary CNS malignant melanoma. Radical excision is the main
modality of treatment. Concurrent chemoradiation in adju-
vant setting for primary CNS malignant melanoma is benefi-
cial.
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